Abiopharma

🔍 McClaskey James Paul (Executive)

Company: INSEEGO CORP. (INSG)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Sold 1,061 shares of Common Stock at $14.14 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 40,962.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 401 shares of Common Stock at $14.14 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 40,561.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units (RSUs) granted on 7/30/2024. The RSU grant was previously reported in Table I of the reporting person's Form 3 filed on 10/2/2024. The vesting schedule for the award was subsequently modified from an initial structure of monthly vesting over four years (with one-fourth vesting on the first anniversary of the grant date and 1/48th vesting monthly thereafter) to a quarterly vesting schedule, including a 7.5% acceleration of vesting.
• F2: Represents shares withheld to cover payment of the tax liabilities of the reporting person related to the vesting of shares from a restricted stock unit (RSU) award that was granted on 12/24/2025. The grant of the RSU was previously reported in Table I of reporting person's Form 4 filed on 12/29/2025.The vesting schedule for the award was subsequently modified from an initial structure of monthly vesting over four years (with one-fourth vesting on the first anniversary of the grant date and 1/48th vesting monthly thereafter) to a quarterly vesting schedule, including a 7.5% acceleration of vesting.